Joe Rogan TRT: A Clinical Interpretation of His Publicly Discussed Hormone Protocol

What Joe Rogan Has Said About TRT

Rogan has been unusually transparent about his hormone use compared to most public figures. On episode #1178 of The Joe Rogan Experience (JRE) with Dr. Rhonda Patrick and across dozens of other episodes, he has described using testosterone replacement therapy, typically framing it as a medical decision tied to aging. He has not provided a single, detailed protocol breakdown in one place, so the public record requires assembling statements across multiple conversations.

Confirmed Statements vs. Inferences

Rogan has directly confirmed testosterone use, NAD+ IV infusions, and vitamin B12 injections. He has referenced growth hormone secretagogues and peptides in favorable terms, though he has not always confirmed personal use of every compound he discusses with guests. Any claim in this article that Rogan "may use" a specific peptide is labeled as inference based on his expressed enthusiasm and the guests he has platformed, not confirmed personal use.

The Podcast as a Primary Source

Because Rogan records thousands of hours of long-form conversation annually, his podcast functions as a de facto primary source. Direct statements made on JRE episodes carry the same evidentiary weight as a published interview. We cite episode numbers where specific claims originate.

Testosterone Replacement Therapy: The Core of the Protocol

TRT forms the foundation of Rogan's publicly described regimen. At 58, he fits squarely within the population most likely to experience clinically meaningful testosterone decline. The Massachusetts Male Aging Study found that total testosterone drops by approximately 1.6% per year after age 40, with free testosterone declining even faster at roughly 2.8% annually [1].

Who Qualifies for TRT Under Current Guidelines

The Endocrine Society's 2018 clinical practice guideline recommends TRT only for men with "unequivocally low serum testosterone concentrations" (consistently below 300 ng/dL on morning draws) combined with signs and symptoms of hypogonadism [2]. Dr. Shalender Bhasin, the guideline's lead author, stated: "We recommend against routinely prescribing testosterone therapy to all older men with low testosterone concentrations" [2]. The distinction between pathological hypogonadism and normal aging remains a source of clinical debate.

Standard Dosing Ranges

Rogan has not publicly specified his exact testosterone dose. For context, standard TRT dosing for male hypogonadism typically falls between 50 and 100 mg of testosterone cypionate or enanthate administered weekly, or 150 to 200 mg every two weeks [2]. The American Urological Association (AUA) recommends titrating to achieve serum testosterone in the mid-normal range of 450 to 600 ng/dL [3]. Supraphysiologic dosing (above 200 mg weekly) crosses from replacement into performance-enhancement territory and carries a different risk profile entirely.

Monitoring Requirements

Any man on TRT requires structured lab monitoring. The Endocrine Society guideline calls for hematocrit checks at baseline, 3 months, 6 months, 12 months, and annually thereafter [2]. Hematocrit above 54% warrants dose reduction or temporary cessation. A 2010 study in the New England Journal of Medicine (the TOM Trial, N=209) was stopped early after men over 65 receiving testosterone gel experienced a higher rate of cardiovascular adverse events compared to placebo [4].

More recent data from the TRAVERSE trial (N=5,246), published in 2023, showed that testosterone replacement in men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [5]. That result shifted the risk-benefit conversation meaningfully.

NAD+ Infusions: What the Evidence Actually Shows

Rogan has discussed NAD+ (nicotinamide adenine dinucleotide) IV infusions on multiple episodes, describing subjective improvements in energy and recovery. NAD+ is a coenzyme present in every living cell, central to mitochondrial energy production and DNA repair.

Preclinical Promise vs. Clinical Gaps

Animal studies have shown that boosting NAD+ levels through precursors like NMN (nicotinamide mononucleotide) can improve metabolic function and extend lifespan in mice. A 2016 study in Cell Metabolism demonstrated that NMN supplementation improved age-associated physiological decline in mice, including better insulin sensitivity and lipid profiles [6]. Human data remains limited. A small randomized trial (N=30) of oral NMN supplementation published in Science in 2022 showed increased NAD+ metabolites in skeletal muscle and improved insulin sensitivity in prediabetic women, but no large-scale RCTs exist for IV NAD+ specifically [7].

IV vs. Oral Routes

The IV route bypasses first-pass metabolism entirely, delivering NAD+ directly to the bloodstream. No FDA-approved indication exists for IV NAD+ infusions. Clinics offering this therapy operate in a regulatory gray zone, and standardization of dosing protocols varies widely. Typical clinic doses range from 250 mg to 1,000 mg per infusion session.

Peptides and Growth Hormone Secretagogues

Rogan has spoken favorably about peptides on numerous episodes, particularly in conversations with guests like Dr. Andrew Huberman and Dr. Mark Gordon. He has referenced compounds including ipamorelin and sermorelin in the context of recovery and body composition.

What Growth Hormone Secretagogues Do

Growth hormone secretagogues (GHS) stimulate the pituitary to release endogenous growth hormone (GH). Sermorelin, a GHRH analogue, has FDA approval for diagnostic evaluation of GH deficiency in children but is used off-label in adult anti-aging protocols. Ipamorelin, a selective ghrelin-receptor agonist, has no FDA approval for any indication.

The Evidence Base

A 2001 study in the Journal of Clinical Endocrinology & Metabolism found that six months of GH replacement in GH-deficient adults improved lean body mass by 2.2 kg and reduced fat mass by 2.5 kg versus placebo [8]. Whether those results translate to GH-sufficient adults taking secretagogues is a separate question. The Endocrine Society explicitly recommends against GH therapy for anti-aging purposes in adults without documented GH deficiency [9]. Dr. Hau Liu, lead author of a systematic review of GH in healthy elderly adults published in the Annals of Internal Medicine, concluded: "The modest gains in lean body mass and the reduction in fat mass observed with growth hormone therapy in healthy elderly persons were accompanied by high rates of adverse events" [10].

Regulatory Field

The FDA issued a safety communication in 2023 tightening oversight of compounded peptides, including certain GHS compounds. BPC-157 and several other peptides were placed on the FDA's "difficult to compound" list, affecting availability through compounding pharmacies. This regulatory shift may affect access to some compounds Rogan has discussed.

Vitamin and Micronutrient Supplementation

Rogan has openly discussed high-dose vitamin supplementation, including IV vitamin drips, oral vitamin D, and various other micronutrients. He has mentioned taking vitamin D3, omega-3 fatty acids, and a multivitamin.

Vitamin D in the Context of TRT

Vitamin D status may interact with testosterone levels. A randomized, double-blind, placebo-controlled trial (N=165) published in Hormone and Metabolic Research found that men receiving 3,332 IU of vitamin D daily for one year showed a significant increase in total testosterone from 10.7 to 13.4 nmol/L compared to no change in the placebo group [11]. This does not mean vitamin D is a testosterone booster per se, but correcting deficiency may remove one drag on endogenous production.

What Matters Clinically

For men on TRT, the supplementation layer is secondary to the exogenous testosterone itself. Vitamin D sufficiency (serum 25-hydroxyvitamin D above 30 ng/mL), adequate omega-3 intake, and baseline micronutrient status are reasonable targets supported by general preventive medicine guidelines, but they do not substitute for proper hormone monitoring.

Cardiovascular Risk: The Question Every TRT Patient Faces

Cardiovascular safety has dominated TRT research for over a decade. Rogan, as a physically active man who trains martial arts and exercises regularly, may carry a different baseline risk than the average TRT candidate, but the data still applies.

TRAVERSE Changed the Conversation

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men, N=5,246) was the first adequately powered cardiovascular outcomes trial for TRT [5]. Published in the New England Journal of Medicine in June 2023, it found no increased risk of major adverse cardiovascular events (MACE) in men aged 45 to 80 with hypogonadism and established cardiovascular disease or multiple risk factors. The hazard ratio for MACE was 0.99 (95% CI: 0.81 to 1.21). This was a non-inferiority trial, not a superiority trial.

What Rogan's Age and Activity Level Mean

A 58-year-old man with consistent high-intensity exercise, no known metabolic disease (based on his public statements), and access to regular medical monitoring is not the same patient as the population enrolled in early safety-signal studies like the TOM Trial [4]. Individualized risk assessment matters. The AUA guidelines state that cardiovascular risk should be evaluated before and during TRT but that TRT is not contraindicated solely on the basis of cardiovascular risk [3].

Fertility Considerations and Exogenous Testosterone

TRT suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone reduces intratesticular testosterone concentration, which can drop sperm production to azoospermic levels in many men. A WHO-sponsored trial of testosterone enanthate (200 mg weekly) for male contraception demonstrated that 65% of men achieved azoospermia within six months [12].

Relevance to Rogan

Rogan has three children and has not publicly expressed interest in future fertility. For men in his demographic who have completed family building, the fertility suppression effect of TRT is a manageable trade-off rather than a contraindication. Men who do wish to preserve fertility while addressing low testosterone may use alternatives like enclomiphene or human chorionic gonadotropin (hCG) to maintain spermatogenesis.

What Rogan's Protocol Tells Us About Celebrity Health Disclosure

Rogan occupies a unique position: he is neither a physician nor a fitness influencer in the traditional sense, yet his platform reaches an estimated 11 million listeners per episode. His willingness to discuss TRT openly has contributed to destigmatizing male hormone therapy, but it also carries the risk that listeners may attempt to replicate a protocol without medical supervision.

The Gap Between Disclosure and Medical Advice

Rogan typically qualifies his statements by noting he works with a physician and that his choices are personal. He does not prescribe protocols. The clinical concern is not with Rogan himself but with the listener who hears "TRT changed my life" and seeks testosterone from an unregulated source without bloodwork or medical oversight. The Endocrine Society, AUA, and every major guideline body require confirmed hypogonadism via laboratory testing before initiating therapy [2][3].

The Monitoring Standard That Applies to Everyone

Whether a patient is a podcast host or a first-time TRT candidate, the monitoring protocol is identical: baseline labs (total testosterone, free testosterone, LH, FSH, hematocrit, PSA, lipid panel), follow-up at 3 and 6 months, then annually. No amount of public confidence in a protocol replaces serial lab verification.

Prostate Safety and PSA Monitoring on TRT

The relationship between testosterone and prostate cancer has been studied for decades. Historical fears that TRT "feeds" prostate cancer trace back to Charles Huggins' 1941 Nobel Prize-winning work on androgen deprivation therapy. Modern evidence has largely revised this view.

What Current Data Shows

A meta-analysis of 22 randomized controlled trials (N=2,351) published in BJU International found no statistically significant increase in prostate cancer incidence among men receiving TRT compared to placebo [13]. The TRAVERSE trial also included a prostate safety endpoint and found no significant difference in high-grade prostate cancer between testosterone and placebo groups [5]. PSA monitoring remains standard: the AUA recommends a baseline PSA before starting TRT and repeat testing at 3 to 6 months, with urological referral for PSA increases exceeding 1.4 ng/mL per year [3].

Bottom Line for Patients Considering a Similar Approach

Rogan's described protocol, TRT plus NAD+ infusions plus peptides plus micronutrient supplementation, represents a "kitchen sink" approach that many longevity-oriented clinics now offer men over 40. The TRT component has the strongest evidence base when used for confirmed hypogonadism. NAD+ and peptide therapies remain in earlier stages of clinical validation. Any man considering this type of regimen should start with morning fasted total and free testosterone levels drawn on two separate occasions, a complete metabolic panel, CBC with hematocrit, lipid panel, and PSA before initiating any hormonal intervention [2][3].